SCHEMBL1406090

SCHEMBL1406090

Cc1cc2c(C)c(F)ccc2[nH]1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 2/20 0.50
NFE2L2 Q16236 1/20 0.50
HRH4 Q9H3N8 1/20 0.47
HPGD P15428 4/20 0.46
GAA P10253 3/20 0.46
CYP1A2 P05177 2/20 0.46
ALDH1A1 P00352 5/20 0.44
KDM4E B2RXH2 4/20 0.44
RXFP1 Q9HBX9 2/20 0.44
MAPT P10636 2/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
NQO2 P16083 1/20 0.42
LMNA P02545 3/20 0.42
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
TP53 P04637 1/20 0.40
ALOX15 P16050 1/20 0.40
MAPK1 P28482 1/20 0.40
HTT P42858 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL32889381 0.83 KEAP1 (0.50) KEAP1NFE2L2HPGDGAACYP1A2
SCHEMBL12475636 0.83 KEAP1 (0.50) KEAP1NFE2L2HPGDGAACYP1A2
SCHEMBL12476349 0.80 DAO (0.56) KEAP1NFE2L2HPGDGAACYP1A2
SCHEMBL4424885 0.79 NQO2 (0.57) KEAP1NFE2L2HPGDGAACYP1A2
SCHEMBL24038450 0.77 KEAP1 (0.45) KEAP1NFE2L2HPGDGAACYP1A2
SCHEMBL10321624 0.77 HRH4 (0.43) KEAP1NFE2L2HRH4HPGDGAA
SCHEMBL22374561 0.77 HRH4 (0.43) KEAP1NFE2L2HRH4HPGDALDH1A1
SCHEMBL22407969 0.77 ALDH1A1 (0.46) KEAP1NFE2L2HPGDGAACYP1A2
SCHEMBL4692767 0.75 DAO (0.53) KEAP1NFE2L2HRH4HPGDGAA
SCHEMBL30605955 0.75 DAO (0.53) KEAP1NFE2L2HRH4HPGDGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1513812-B1 SUBSTITUTED INDOLES ASTRAZENECA AB (SE) 2011-03-09 EP disclosed
US-20100210685-A1 Novel Substituted Indoles ASTRAZENECA AB (SE) 2010-08-19 US disclosed
US-7754735-B2 Substituted indoles ASTRAZENECA AB (SE) 2010-07-13 US disclosed
CN-100404505-C Novel substituted indoles ASTRAZENECA AB (SE) 2008-07-23 CN disclosed
US-7166607-B2 Substituted indoles ASTRAZENECA AB (SE) 2007-01-23 US disclosed
US-20050222201-A1 such as 3-(2-chloro-4-quinolinyl)-2,5-dimethyl-1H-indole-1-acetic acid, used for treating respiratory system disorders and as inhibitors of G protein-coupled receptor chemoattractant homologous receptor expressed on lymphocyte cells (CRTH2) ASTRAZENECA AB (SE) 2005-10-06 US disclosed
CN-1671659-A Novel substituted indoles ASTRAZENECA AB (SE) 2005-09-21 CN disclosed
US-20050165055-A1 Novel substituted indoles ASTRAZENECA AB (SE) 2005-07-28 US disclosed
EP-1513812-A1 SUBSTITUTED INDOLES AstraZeneca AB (SE) 2005-03-16 EP disclosed
WO-2003101961-A1 NOVEL SUBSTITUTED INDOLES ASTRAZENECA AB (SE) 2003-12-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100210685-A1 Novel Substituted Indoles IDO1, IDO2, TPH1 KEAP1 410/4885NFE2L2 186/4885HRH4 107/4885
US-20050165055-A1 Novel substituted indoles IDO1, IDO2, TPH1 KEAP1 353/4885NFE2L2 187/4885HRH4 106/4885
US-20050222201-A1 such as 3-(2-chloro-4-quinolinyl)-2,5-dimethyl-1H-indole-1-acetic acid, used for treating respiratory system disorders and as inhibitors of G protein-coupled receptor chemoattractant homologous receptor expressed on lymphocyte cells (CRTH2) HRH2, HRH1, HCAR2 KEAP1 739/4885NFE2L2 697/4885HRH4 11/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.